Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ascorbic acid and adriamycin toxicity.

K Shimpo1, T Nagatsu, K Yamada

  • 1Institute for Comprehensive Medical Science, School of Medicine, Fujita Health University, Aichi, Japan.

The American Journal of Clinical Nutrition
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive values of immune indicators on respiratory failure in the early phase of COVID-19 due to Delta and precedent variants.

Frontiers in immunology·2023
Same author

Recurrent deep vein thrombosis with a protein S Tokushima mutation.

The British journal of dermatology·2017
Same author

31 years of clinical hemorheology and microcirculation.

Clinical hemorheology and microcirculation·2012
Same author

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.

Leukemia·2006
Same author

Antiangiogenic activity of curcumin in hepatocellular carcinoma cells implanted nude mice.

Clinical hemorheology and microcirculation·2005
Same author

Quantitative assessment of cerebral neocapillary network and its remodeling in mice using intravital fluorescence videomicroscopy.

Angiogenesis·2003

Adriamycin (ADR) chemotherapy can cause heart damage. Ascorbic acid, an antioxidant, did not affect ADR

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Adriamycin (ADR) is a potent chemotherapy drug effective against various human neoplasms.
  • A significant limitation of ADR therapy is its cardiotoxicity, potentially mediated by lipid peroxidation in cardiac tissues.
  • Ascorbic acid is a well-known antioxidant with potential to mitigate oxidative stress.

Purpose of the Study:

  • To investigate the efficacy of ascorbic acid in reducing Adriamycin-induced toxicity, particularly cardiotoxicity.
  • To evaluate the impact of ascorbic acid on the antitumor activity and overall survival in ADR-treated animals.
  • To assess the protective effects of ascorbic acid against ADR-induced cardiac damage at a cellular level.

Main Methods:

  • Animal models (mice and guinea pigs) were used to assess ADR toxicity and the effects of ascorbic acid.

Related Experiment Videos

  • Antitumor activity was evaluated in mice bearing leukemia L1210 or Ehrlich ascites carcinoma.
  • Lipid peroxide levels in cardiac tissue and ultrastructural changes in the heart were analyzed.
  • Survival rates of animals treated with ADR alone versus ADR combined with ascorbic acid were compared.

    • Main Results:

    • Ascorbic acid did not compromise the antitumor efficacy of ADR against tested neoplasms.
    • Ascorbic acid significantly prolonged the survival of animals treated with ADR.
    • ADR treatment increased lipid peroxide levels in mouse hearts, an effect prevented by ascorbic acid.
    • Electron microscopy confirmed that ascorbic acid significantly prevented ADR-induced cardiomyopathy in guinea pigs.

    Conclusions:

    • Ascorbic acid demonstrates a protective effect against Adriamycin-induced cardiotoxicity without diminishing its anticancer activity.
    • Ascorbic acid and its derivatives show potential for mitigating both general and cardiac toxicity associated with ADR therapy.
    • Combined treatment with ADR and ascorbic acid or its derivatives may offer a safer and more effective therapeutic strategy for cancer patients.